|
1
|
McDonald KL, O'Sullivan MG, Parkinson JF,
Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook
RJ, et al: IQGAP1 and IGFBP2: Valuable biomarkers for determining
prognosis in glioma patients. J Neuropathol Exp Neurol. 66:405–417.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H, Ma L, Wang Q, Zheng X, Wu C and
Xu BN: Role of magnetic resonance spectroscopy for the
differentiation of recurrent glioma from radiation necrosis: A
systematic review and meta-analysis. Eur J Radiol. 83:2181–2189.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY
and Jiang XB: Dendritic cell-based vaccine for the treatment of
malignant glioma: A systematic review. Cancer Invest. 32:451–457.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Balenci L, Clarke ID, Dirks PB, Assard N,
Ducray F, Jouvet A, Belin MF, Honnorat J and Baudier J: IQGAP1
protein specifies amplifying cancer cells in glioblastoma
multiforme. Cancer Res. 66:9074–9082. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walbert T and Chasteen K: Palliative and
supportive care for glioma patients. Cancer Treat Res. 163:171–184.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Newlands ES, Stevens MF, Wedge SR,
Wheelhouse RT and Brock C: Temozolomide: A review of its discovery,
chemical properties, pre-clinical development and clinical trials.
Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stevens MF, Hickman JA, Langdon SP, Chubb
D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, et
al: Antitumor activity and pharmacokinetics in mice of
8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one
(CCRG 81045; M & B 39831), a novel drug with potential as an
alternative to dacarbazine. Cancer Res. 47:5846–5852.
1987.PubMed/NCBI
|
|
9
|
Lewis TS, Shapiro PS and Ahn NG: Signal
transduction through MAP kinase cascades. Adv Cancer Res.
74:49–139. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rubinfeld H and Seger R: The ERK cascade:
A prototype of MAPK signaling. Mol Biotechnol. 31:151–174. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luttrell LM: ‘Location, location,
location’: Activation and targeting of MAP kinases by G
protein-coupled receptors. J Mol Endocrinol. 30:117–126. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Auf G, Jabouille A, Delugin M, Guérit S,
Pineau R, North S, Platonova N, Maitre M, Favereaux A, Vajkoczy P,
et al: High epiregulin expression in human U87 glioma cells relies
on IRE1α and promotes autocrine growth through EGF receptor. BMC
Cancer. 13:5972013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clara CA, Marie SK, de Almeida JR,
Wakamatsu A, Oba-Shinjo SM, Uno M, Neville M and Rosemberg S:
Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1α in
human glioblastoma. Neuropathology. 34:343–352. 2014.PubMed/NCBI
|
|
14
|
Li L, Puliyappadamba VT, Chakraborty S,
Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P,
Burma S, et al: EGFR wild type antagonizes EGFRvIII-mediated
activation of Met in glioblastoma. Oncogene. 34:129–134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burrell K, Singh S, Jalali S, Hill RP and
Zadeh G: VEGF regulates region-specific localization of
perivascular bone marrow-derived cells in Glioblastoma. Cancer Res.
74:3727–3739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie J, Ma YH, Wan M, Zhan RY and Zhou YQ:
Expression of dedifferentiation markers and multilineage markers in
U251 glioblastoma cells with silenced EGFR and FGFR genes. Oncol
Lett. 7:131–136. 2014.PubMed/NCBI
|
|
17
|
Zheng H, Ying H, Yan H, Kimmelman AC,
Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al: p53
and Pten control neural and glioma stem/progenitor cell renewal and
differentiation. Nature. 455:1129–1133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Höland K, Boller D, Hagel C, Dolski S,
Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, et al:
Targeting class IA PI3K isoforms selectively impairs cell growth,
survival, and migration in glioblastoma. PLoS One. 9:e941322014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun Y, Zhang W, Chen D, Lv Y, Zheng J,
Lilljebjörn H, Ran L, Bao Z, Soneson C, Sjögren HO, et al: A glioma
classification scheme based on coexpression modules of EGFR and
PDGFRA. Proc Natl Acad Sci USA. 111:3538–3543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee JS, Xiao J, Patel P, Schade J, Wang J,
Deneen B, Erdreich-Epstein A and Song HR: A novel tumor-promoting
role for nuclear factor IA in glioblastomas is mediated through
negative regulation of p53, p21, and PAI1. Neuro Oncol. 16:191–203.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holland EC, Celestino J, Dai C, Schaefer
L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in
neural progenitors induces glioblastoma formation in mice. Nat
Genet. 25:55–57. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
McNamara MG, Sahebjam S and Mason WP:
Emerging biomarkers in glioblastoma. Cancers (Basel). 5:1103–1119.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rios A, Hsu SH, Blanco A, Buryanek J, Day
AL, McGuire MF and Brown RE: Durable response of glioblastoma to
adjuvant therapy consisting of temozolomide and a weekly dose of
AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib,
metformin and niacinamide. Oncoscience. 3:156–163. 2016.PubMed/NCBI
|
|
24
|
Berte N, Piee-Staffa A, Piecha N, Wang M,
Borgmann K, Kaina B and Nikolova T: Targeting homologous
recombination by pharmacological inhibitors enhances the killing
response of glioblastoma cells treated with alkylating drugs. Mol
Cancer Ther. 15:2665–2678. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shaaban S, Alsulami M, Arbab SA, Ara R,
Shankar A, Iskander A, Angara K, Jain M, Bagher-Ebadian H, Achyut
BR and Arbab AS: Targeting bone marrow to potentiate the anti-tumor
effect of tyrosine kinase inhibitor in preclinical rat model of
human glioblastoma. Int J Cancer Res. 12:69–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qiu Z, Yue S, Chang J and Wang G:
Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses
proliferation and promotes apoptosis of U251 glioblastoma cells. Xi
Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:936–939. 2016.PubMed/NCBI
|
|
27
|
Favata M, Horiuchi KY, Manos EJ, Daulerio
AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F,
et al: Identification of a novel inhibitor of mitogen-activated
protein kinase kinase. J Biol Chem. 273:18623–18632. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DeSilva D, Jones EA, Favata MF, Jaffee BD,
Magolda RL, Trzaskos JM and Scherle PA: Inhibition of
mitogen-activated protein kinase kinase blocks T cell proliferation
but does not induce or prevent anergy. J Immunol. 160:4175–4181.
1998.PubMed/NCBI
|
|
29
|
Duncia JV, Santella JB, Higley CA, Pitts
WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC,
Teleha CA, et al: MEK inhibitors: The chemistry and biological
activity of U0126, its analogs, and cyclization products. Bioorg
Med Chem Lett. 8:2839–2844. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Son S, Kim KT, Cho DC, Kim HJ, Sung JK and
Bae JS: Curcumin stimulates proliferation of spinal cord neural
progenitor cells via a mitogen-activated protein kinase signaling
pathway. J Korean Neurosurg Soc. 56:1–4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen X, Xie Q, Cheng X, Diao X, Cheng Y,
Liu J, Xie W, Chen Z and Zhu B: Role of interleukin-17 in
lymphangiogenesis in non-small-cell lung cancer: Enhanced
production of vascular endothelial growth factor C in
non-small-cell lung carcinoma cells. Cancer Sci. 101:2384–2390.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu C, Qi X, Chen Y, Sun B, Dai Y and Gu
Y: PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in
IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res
Clin Oncol. 137:1587–1594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou X, Liao X, Zhang B, He H, Shui Y, Xu
W, Jiang C, Shen L and Wei Q: Recurrence patterns in patients with
high-grade glioma following temozolomide-based chemoradiotherapy.
Mol Clin Oncol. 5:289–294. 2016.PubMed/NCBI
|
|
34
|
Dong F: Metalloproteases involved in the
Temozolomide (TMZ) resistance of U87-MG glioma cells. Angenommen
vom Fachbereich Medizin der Philipps-Universität Marburg. April
3–2013.
|
|
35
|
Balmanno K and Cook SJ: Tumour cell
survival signalling by the ERK1/2 pathway. Cell Death Differ.
16:368–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Neuzillet C, Tijeras-Raballand A, de
Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer
therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yoon S and Seger R: The extracellular
signal-regulated kinase: Multiple substrates regulate diverse
cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gentile MT, Ciniglia C, Reccia MG,
Volpicelli F, Gatti M, Thellung S, Florio T, Melone MA and
Colucci-D'Amato L: Ruta graveolens L. induces death of glioblastoma
cells and neural progenitors, but not of neurons, via ERK 1/2 and
AKT activation. PLoS One. 10:e01188642015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X,
Liu Z, Gong Y and Shao C: Berberine induces senescence of human
glioblastoma cells by downregulating the EGFR-MEK-ERK signaling
pathway. Mol Cancer Ther. 14:355–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han S, Li Z, Master LM, Master ZW and Wu
A: Exogenous IGFBP-2 promotes proliferation, invasion, and
chemoresistance to temozolomidein glioma cells via the integrin
β1-ERK pathway. Br J Cancer. 111:1400–1409. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tacconi C, Correale C, Gandelli A,
Spinelli A, Dejana E, D'Alessio S and Danese S: Vascular
endothelial growth factor C disrupts the endothelial lymphatic
barrier to promote colorectal cancer invasion. Gastroenterology.
148:1438–1451.e8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Carpenter RL, Paw I, Zhu H, Sirkisoon S,
Xing F, Watabe K, Debinski W and Lo HW: The gain-of-function GLI1
transcription factor TGLI1 enhances expression of VEGF-C and TEM7
to promote glioblastoma angiogenesis. Oncotarget. 6:22653–22665.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pang XH, Tian H, Liu ZY, Li SM, Liu ST and
Tian GP: Significance and expression of vascular endothelial growth
factor-C (VEGF-C) in esophageal squamous carcinoma and glioma. Ai
Zheng. 22:1166–1169. 2003.(In Chinese). PubMed/NCBI
|
|
45
|
Wang CA, Harrell JC, Iwanaga R, Jedlicka P
and Ford HL: Vascular endothelial growth factor C promotes breast
cancer progression via a novel antioxidant mechanism that involves
regulation of superoxide dismutase 3. Breast Cancer Res.
16:4622014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Varney ML and Singh RK: VEGF-C-VEGFR3/Flt4
axis regulates mammary tumor growth and metastasis in an autocrine
manner. Am J Cancer Res. 5:616–628. 2015.PubMed/NCBI
|
|
47
|
Sun GG, Wang YD, Cui DW, Cheng YJ and Hu
WN: EMP1 regulates caspase-9 and VEGFC expression and suppresses
prostate cancer cell proliferation and invasion. Tumour Biol.
35:3455–3462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Khromova N, Kopnin P, Rybko V and Kopnin
BP: Downregulation of VEGF-C expression in lung and colon cancer
cells decelerates tumor growth and inhibits metastasis via multiple
mechanisms. Oncogene. 31:1389–1397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen Y, Jiang L, She F, Tang N, Wang X, Li
X, Han S and Zhu J: Vascular endothelial growth factor-C promotes
the growth and invasion of gallbladder cancer via an autocrine
mechanism. Mol Cell Biochem. 345:77–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Su JL, Chen PS, Chien MH, Chen PB, Chen
YH, Lai CC, Hung MC and Kuo ML: Further evidence for expression and
function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell.
13:557–560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH,
Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The
VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
Cancer Cell. 9:209–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Timoshenko AV, Rastogi S and Lala PK:
Migration-promoting role of VEGF-C and VEGF-C binding receptors in
human breast cancer cells. British J Cancer. 97:1090–1098. 2007.
View Article : Google Scholar
|
|
53
|
Takahashi O, Komaki R, Smith PD,
Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ,
Korshunova MV, Biernacka A, et al: Combined MEK and VEGFR
inhibition in orthotopic human lung cancer models results in
enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Clin Cancer Res. 18:1641–1654. 2012. View Article : Google Scholar : PubMed/NCBI
|
